Transgene Biotek Ltd Stock Price Today (NSE: TRABI)
Fundamental Score
Transgene Biotek Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Transgene Biotek Ltd share price today is ₹3.10, down 1.59% on NSE/BSE as of 1 June 2026. Transgene Biotek Ltd (TRABI) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹26.14 (Cr). The 52-week high for TRABI share price is ₹5.26 and the 52-week low is ₹1.83. The company has a Return on Equity (ROE) of -6.56% and a debt-to-equity ratio of 1.79.
Transgene Biotek Ltd Share Price Chart — NSE/BSE Historical Performance
Transgene Biotek Ltd share price chart: 11.85% return over the past month. 52-week high ₹5.26, 52-week low ₹1.83.
Transgene Biotek Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3.29 | ₹3.29 | ₹3.09 | ₹3.21 | 47.93K (Cr) | |
| ₹3.20 | ₹3.20 | ₹3.11 | ₹3.13 | 3.19K (Cr) | |
| ₹3.12 | ₹3.35 | ₹3.02 | ₹3.26 | 62.49K (Cr) | |
| ₹3.24 | ₹3.35 | ₹2.92 | ₹3.06 | 21.84K (Cr) | |
| ₹3.05 | ₹3.44 | ₹3.05 | ₹3.17 | 21.25K (Cr) | |
| ₹3.35 | ₹3.35 | ₹3.01 | ₹3.15 | 28.33K (Cr) | |
| ₹3.08 | ₹3.30 | ₹2.90 | ₹3.09 | 96.91K (Cr) | |
| ₹3.49 | ₹3.49 | ₹3.11 | ₹3.14 | 30.08K (Cr) | |
| ₹3.05 | ₹3.38 | ₹3.05 | ₹3.20 | 89.17K (Cr) | |
| ₹3.40 | ₹3.40 | ₹2.90 | ₹3.11 | 86.58K (Cr) |
Transgene Biotek Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2.98 | ₹3.50 | ₹2.82 | ₹3.21 | +7.72% | |
| ₹1.98 | ₹3.20 | ₹1.98 | ₹2.75 | +38.89% | |
| ₹2.67 | ₹3.11 | ₹1.91 | ₹1.98 | -25.84% | |
| ₹2.31 | ₹3.17 | ₹1.83 | ₹2.67 | +15.58% | |
| ₹3.29 | ₹3.29 | ₹1.90 | ₹2.06 | -37.39% | |
| ₹3.67 | ₹3.67 | ₹2.59 | ₹3.15 | -14.17% | |
| ₹3.97 | ₹4.19 | ₹3.23 | ₹3.61 | -9.07% | |
| ₹3.98 | ₹4.39 | ₹3.21 | ₹3.78 | -5.03% | |
| ₹3.57 | ₹4.50 | ₹3.43 | ₹3.96 | +10.92% | |
| ₹4.74 | ₹5.17 | ₹3.68 | ₹3.88 | -18.14% | |
| ₹4.63 | ₹5.26 | ₹4.25 | ₹4.55 | -1.73% | |
| ₹4.21 | ₹4.64 | ₹3.92 | ₹4.44 | +5.46% |
AI Research Briefing
Powered by Gemini · 2026-04-13
This micro-cap R&D play is a lottery ticket, not a sustainable business.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The stock price has slightly decreased by -0.75% from its previous close. Transgene Biotek's board approved the unaudited financial results for the quarter ended December 31, 2025, on February 13, 2026.
CORE STORY (THE REAL GAME)
Transgene Biotek is not a healthcare service provider, it's a micro-cap R&D play in oncology and drug delivery. The market is treating it as a lottery ticket on a successful drug development breakthrough, not a going concern.
- R&D pipeline hopes
- Micro-cap mania
- Successful clinical trial results
- Major partnership or licensing deal
- Acquisition by a larger pharmaceutical company
- Micro/SME cap liquidity risk
- Negative profitability and free cash flow
- High debt and poor interest coverage
No FII/DII interest. Promoter holding stagnant at 23.64%.
Healthcare sector in India is growing, but Transgene Biotek's financial instability makes it unlikely to benefit.
No. Free Cash Flow 5Y: ₹-0.42 Cr
In the next 3-6 months, continued losses and lack of revenue growth will likely lead to further stock decline. Avoid unless there's concrete news of a major R&D breakthrough.
Primary Thesis Risk
R&D failure and eventual insolvency.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Transgene Biotek Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Transgene Biotek Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TRABI across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (-6.56%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-1.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-411.11%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-457.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-16.67%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.79)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-1.25x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.42 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (23.64%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Transgene Biotek Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Transgene Biotek Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Transgene Biotek LtdTransgene Biote...Selected✓ TRABI • 526139 | 0.5/100 | ₹3.10₹3 | ₹26.14₹26.14 | — — | -6.56%Poor -6.56% Poor | -1.75%Poor -1.75% Poor | 1.79Average 1.8 Average | 14.15%Good 14.15% Good | — — | 0.00% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 64.3/100 | ₹1577.30₹1577 | ₹25557.40₹25557.40 | 47.83Average 47.8 Average | 24.30%Excellent 24.30% Excellent | 28.88%Excellent 28.88% Excellent | 0.07Excellent 0.1 Excellent | 16.69%Excellent 16.69% Excellent | 13.09%Good 13.09% Good | 0.79% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 53.7/100 | ₹1240.90₹1241 | ₹10272.45₹10272.45 | 67.39Average 67.4 Average | 19.00%Good 19.00% Good | 20.91%Excellent 20.91% Excellent | 0.42Excellent 0.4 Excellent | 18.97%Excellent 18.97% Excellent | 15.00%Excellent 15.00% Excellent | 0.20% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 48.9/100 | ₹540.85₹541 | ₹10124.28₹10124.28 | 63.98Average 64.0 Average | 11.53%Average 11.53% Average | 14.66%Average 14.66% Average | 0.14Excellent 0.1 Excellent | -0.56%Poor -0.56% Poor | 9.22%Good 9.22% Good | 0.20% |
Thyrocare Technologies LtdThyrocare Techn... THYROCARE • 539871 | 40.5/100 | ₹522.35₹522 | ₹7724.80₹7724.80 | 60.48Average 60.5 Average | 16.15%Good 16.15% Good | 24.78%Excellent 24.78% Excellent | 0.05Excellent 0.1 Excellent | -0.64%Poor -0.64% Poor | 9.62%Good 9.62% Good | 1.44% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 39.6/100 | ₹541.60₹542 | ₹2626.09₹2626.09 | 30.73Average 30.7 Average | 9.29%Poor 9.29% Poor | 12.52%Average 12.52% Average | 0.30Excellent 0.3 Excellent | 22.05%Excellent 22.05% Excellent | 21.41%Excellent 21.41% Excellent | 0.34% |
Suraksha Diagnostic LtdSuraksha Diagno... SURAKSHA • 544293 | 47.1/100 | ₹281.70₹282 | ₹1534.08₹1534.08 | 48.05Average 48.0 Average | 16.46%Good 16.46% Good | 17.84%Good 17.84% Good | 0.51Good 0.5 Good | 16.38%Excellent 16.38% Excellent | 9.86%Good 9.86% Good | 0.00% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 66.1/100 | ₹1105.25₹1105 | ₹1080.56₹1080.56 | 22.01Average 22.0 Average | 19.40%Good 19.40% Good | 25.75%Excellent 25.75% Excellent | 0.00Excellent 0.0 Excellent | 44.03%Excellent 44.03% Excellent | 27.29%Excellent 27.29% Excellent | 0.32% |
One Global Service Provider IncOne Global Serv... ONEGLOBAL • 514330 | 69.5/100 | ₹467.55₹468 | ₹1070.08₹1070.08 | 24.39Average 24.4 Average | 42.31%Excellent 42.31% Excellent | 56.38%Excellent 56.38% Excellent | 0.00Excellent 0.0 Excellent | 128.82%Excellent 128.82% Excellent | — — | 0.00% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 40.3/100 | ₹307.25₹307 | ₹1042.27₹1042.27 | — — | 4.63%Poor 4.63% Poor | -1.33%Poor -1.33% Poor | 0.01Excellent 0.0 Excellent | 23.31%Excellent 23.31% Excellent | 24.47%Excellent 24.47% Excellent | 0.00% |
46.5/100 | ₹228.70₹229 | ₹826.72₹826.72 | 30.47Average 30.5 Average | 27.08%Excellent 27.08% Excellent | 28.85%Excellent 28.85% Excellent | 0.48Excellent 0.5 Excellent | — — | — — | 0.00% | |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price25557.40 Cr
- Vijaya Diagnostic Centre Ltd share price10272.45 Cr
- Metropolis Healthcare Ltd share price10124.28 Cr
- Thyrocare Technologies Ltd share price7724.80 Cr
- Krsnaa Diagnostics Ltd share price2626.09 Cr
Transgene Biotek Ltd Quarterly Performance
Latest quarterly metrics for TRABI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-16.67%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-457.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
14.15%
Compounded annual net profit growth over 5 years
Transgene Biotek Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TRABI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Transgene Biotek Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Transgene Biotek Ltd (TRABI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Transgene Biotek Ltd
About TRABI (Transgene Biotek Ltd)
Transgene Biotek Ltd is a pioneering force in healthcare service provision, dedicated to advancing the frontiers of medical science through cutting-edge research and development. T...he company specializes in crafting innovative solutions designed to meet the evolving needs of the pharmaceutical industry and, ultimately, improve patient outcomes. Their core focus lies in developing a diverse range of therapeutic interventions, with a strong emphasis on precision medicine and targeted therapies. Transgene Biotek Ltd is committed to upholding the highest ethical standards and scientific rigor in all their endeavors, ensuring that their contributions translate into tangible benefits for global healthcare systems. At the heart of Transgene Biotek Ltd's operations is a steadfast commitment to enhancing the accessibility and affordability of life-saving medications. This is achieved through strategic investments in the development of biogenerics, offering cost-effective alternatives to established branded drugs. Furthermore, the company explores novel drug delivery systems, aiming to optimize drug efficacy and patient compliance. Their research spans a wide spectrum of therapeutic areas, from oncology to immunology, reflecting a holistic approach to addressing unmet medical needs. Transgene Biotek Ltd prides itself on its collaborative partnerships with leading academic institutions and pharmaceutical companies, fostering a dynamic ecosystem for innovation. Transgene Biotek Ltd is more than just a healthcare service provider; it is a catalyst for positive change within the medical landscape. The company operates with a clear vision: to transform scientific discoveries into real-world solutions that empower individuals to live healthier and more fulfilling lives. Through continuous investment in research, talent development, and technological advancement, Transgene Biotek Ltd is shaping the future of healthcare. Their dedication to innovation and patient-centricity makes them a valuable partner in the ongoing quest to improve the human condition.
Company Details
Key Leadership
TRABI Share Price: Frequently Asked Questions
What is the current share price of Transgene Biotek Ltd?
Transgene Biotek Ltd (TRABI) trades at ₹3.10 on NSE and BSE. Market cap ₹26.14 (Cr). Educational data only.
What is the P/E ratio of Transgene Biotek Ltd?
Transgene Biotek Ltd has a P/E of N/Ax vs industry average 39.28x.
What is the Bull Run score for Transgene Biotek Ltd?
Transgene Biotek Ltd has a Bull Run score of 0.5/100 based on 25+ financial parameters.
Does Transgene Biotek Ltd pay dividends?
Transgene Biotek Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Transgene Biotek Ltd?
Transgene Biotek Ltd has ROE of -6.56%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Transgene Biotek Ltd?
Transgene Biotek Ltd has debt-to-equity of 1.79.
Is Transgene Biotek Ltd a good investment?
Bull Run gives Transgene Biotek Ltd a score of 0.5/100. This is not investment advice — consult a SEBI-registered advisor.